UCSF Helen Diller Family Comprehensive Cancer Center
Protocol Search Results
273 protocols in [Age Group: A]

[ Print this page ]

Protocol No.Title
05161131-I-Metaiodobenzylguanidine (131-I-MIBG) Therapy for Refractory Neuroblastoma: A Best Available Therapy/Compassionate Use Protocol
097517I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2)
09994131I-Metaiodobenzylguanidine(131I-MIBG) Therapy for Patients with Malignant Pheochromocytoma & Related Tumors
10-00353Mediators of Atherosclerosis in South Asians Living in America
10082An Expanded Access Study of the Feasibility of Using the CliniMACS® Device for CD34+ Cell Selection and T Cell Depletion for Graft-versus-Host Disease Prophylaxis in Alternative Donor Stem Cell Transplant Recipients
10758A Registry Study of the Penguin Cold Cap Used for Prevention of Hair Loss in Breast Cancer Patients Receiving Chemotherapy
112516A Multicenter Phase I Dose-Finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax®) in Combination with Doxorubicin HCl Liposomal (or Doxil®) for the Treatment of Adults with Relapsed or Refractory T-cell Lymphomas
11996A Phase 1b/ll Study of Eribulin in Combination with Cyclophosphamide in Patients with Solid Tumor Malignancies
120817Phase II Study of Everolimus for Recurrent or Progressive Low-Grade Gliomas in Children
120819Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children and Young Adults with Recurrent/Refractory BRAFV600E- or BRAF Ins T-mutant Brain Tumors
12084Pediatric Myelodysplastic Syndrome and Bone Marrow Failure Disorder Registry and Tissue Repository
12088124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients with Neuroblastoma: A Pilot Study
122011A Phase II Study of Radiation Therapy and Vismodegib, for the Treatment of Locally Advanced Basal Cell Carcinoma of the Head and Neck
12557A Randomized Phase 2 Trial of Immediate versus Delayed Anti-CTLA4 Blockade Following Sipuleucel-T Treatment for Prostate Cancer Immunotherapy
127522Translating Cancer Genetics for the Safety Net Setting
127536Evaluation of Intra-Operative Ultrasound Guided Excision using the Hydromark Clip as an Alternative to Needle Localization for Non-Palpable Breast Lesions
129812Isolation and evaluation of circulating tumor cells (CTCs) from patients with prostate, pancreatic, lung, kidney and bladder cancers.
12985The Effect of Tyrosine Kinase Inhibitors on Male Reproductive Health and Spermatozoa Function: A Prospective Observational Study of Men Receiving TKI for Treatment of Malignant Tumors
13-12236Pathogen and Autoantibody Discovery in Unexplained Diseases of the Nervous System
131012PI3K/mTOR Pathway Activation-Stratified Phase II Study of RAD001 (Everolimus) with and without Temozolomide in the Treatment of Adult Patients with Supratentorial Low-Grade Glioma
13553Prostate Cancer Decision Making for Low-Income African American Men
13802A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain
138510Tissue Bank of Human Biospecimens for Molecular Studies of Mechanisms of Resistance or Response to Therapy in Melanoma and Other Solid Tumors: UCSF Melanoma Tissue Bank (MTB)
13852Melanoma Biomarkers in Blood
139510Phase Ib Study of Ficlatuzumab with High Dose Cytarabine in Relapsed and Refractory AML
139511A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination with Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma
14-13118Effects of IUDs and levonorgestrel on the mucosal immune environment in the female reproductive tract
14-13322Accelerated ultrasound ablation of uterine fibroids with MR guided vascular targeting - A pilot study
14-13899Concomitant Administration of FSH With A Low Dose Of hCG (1500 IU) Has Equivalent Oocyte Developmental Competence While Decreasing The Exposure To hCG In In Vitro Fertilization Cycles: A Double –Blind Randomized Control Trial
14-14248Development of a Multi-Ethnic, Multimodal Obesity Cohort
14-14352TREATMENT OF TYPE 1 DIABETES BY ISLET TRANSPLANTATION INTO THE GASTROINTESTINAL SUBMUCOSA
14082A Pilot Trial Testing the Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan in Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)
14083An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescent Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 Mutations
14251A Phase Ib Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory non-Hodgkin Lymphoma
144515Perioperative Stromal Depletion Strategies in Pancreatic Ductal Adenocarcinoma
144526A Pilot Study of PET/MRI Localization of Yitrrium-90 Microspheres Following Hepatic Radioembolization in Patients with Liver Malignancies
14524A Phase II Study of the Anti-PD-L1 Antibody MPDL3280A in Subjects with Non-Metastatic Transitional Cell Carcinoma of the Bladder
14559An Open Label, Randomized Phase 2 Trial of Prostvac and Ipilimumab as Monotherapy or in Combination for Men with Localized Prostate Cancer Undergoing Radical Prostatectomy
14636Does Real World Exposure to FDA Graphic Warnings Affect Tobacco Use Behavior?
147522Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II study with Pharmacodynamics Markers (TBCRC035)
147523Reversing Therapy Resistance with Epigenetic-Immune Modification (Pembrolizumab, Vorinostat, Tamoxifen)
147531Biomarker and Phenotypic Risk Factors for Breast Cancer Lymphedema
148511Determine the Prevalence of Kinase Fusions in Patients with Metastatic Melanoma in Need of Treatment
14859Phase II Trial of Targeted Kinase Fusion Inhibition in Unresectable Stage III/IV BRAF/NRAS Wild-Type Melanoma
149510A Phase 1 Study of ES414 in Patients with Metastatic Castration-Resistant Prostate Cancer
15-16368Multi-center Randomized Controlled Trial of Refeeding in Anorexia Nervosa.
150812PNOC 005: A Phase 1 Study of Modified Measles Virus (MV-NIS) for the Treatment of Children and Young Adults with Recurrent Medulloblastoma or Recurrent Atypical Teratoid Rhabdoid Tumors (ATRT)
150814Multicenter Cohort Study To Evaluate Outcomes after Receipt of Targeted Therapy Matched to an Individualized Cancer Therapy (iCat) Recommendations in Children and Young Adults with Recurrent, Refractory, or High Risk Solid Tumors: The iCat2, GAIN Consortium Study
150816A Phase I Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
150818Phase II Study of Clofarabine in Patients with Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
15084Discovering Therapeutic Targets Using Circulating Tumor DNA in Pediatric Patients with Solid and CNS Malignancies: A Pilot Study
151011A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients with Advanced Solid Tumors, Including Gliomas, with an IDH1 and/or IDH2 Mutation
151013A Feasibility Study of Gallium-68 Citrate PET to Detect Hyperactive mTOR Activity in Glioma
15103Pilot Randomized Neo-adjuvant Evaluation of Poly-ICLC-Assisted Tumor Lysate Vaccines in Adult Patients with WHO Grade II Glioma
15105Brain Tumor Funders’ Collaborative: Molecular Genetic, Host-Derived and Clinical Determinants of Long-Term Survival in Glioblastoma
15108Pilot Randomized Neo-Adjuvant Evaluation of Agonist Anti-CD27 Monoclonal Antibody Varlilumab on Immunologic Activities of IMA950 Vaccine plus Poly-ICLC in Patients with WHO Grade II Low-Grade Glioma (LGG)
15109A Phase 1a/1b Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers
152010A Multicenter, Randomized, Open-label, Phase III Clinical Trial of Gemcitabine and Carboplatin followed by Epstein-Barr Virus-specific Autologous Cytotoxic T-Lymphocytes versus Gemcitabine and Carboplatin as First Line Treatment for Advanced Nasopharyngeal Carcinoma Patients
15205SPORE (Specialized Program of Research Excellence) in Head and Neck Cancer
152514A Phase II Study of IRD (Ixazomib, Lenalidomide, and Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
152516A PHASE 1/2, OPEN-LABEL, UNCONTROLLED, MULTIPLE-DOSE ESCALATION, COHORT EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF ASN002 IN RELAPSED/REFRACTORY LYMPHOMA, MYELOFIBROSIS, CHRONIC LYMPHOCYTIC LEUKEMIA AND ADVANCED SOLID TUMORS
152519Clinical-Grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell Malignancies (MMRF-002)
154520Lifestyle and Patient Outcomes after Gastrointestinal Cancer: A Prospective Cohort Study (LACE)
154521Gallium-68 Citrate PET to Detect MYC Amplification and Transferring Receptor Expression in Hepatocellular Carcinoma (HCC)
154526Identification of Molecular Determinants of Esophageal Cancer in Tanzania (MDEC-TZ)
155510A Clinical Trial of High-Intensity Aerobic and Resistance Exercise for Metastatic Prostate Cancer
155513A Randomized Controlled Clinical Trial of a Smartphone-Based App to Improve Urinary and Sexual Function Outcomes after Robot-Assisted Laparoscopic Radical Prostatectomy Surgery
155518Precision Oncology and Molecular Targeting in Advanced Prostate Cancer: Identifying Predictive Markers of Response (The "PROMOTE" Study)
15632Mobile Technology to Improve Treatment Engagement and Outcomes in Smokers with Post-Traumatic Stress Disorder:Pilot
15635Clinical Pharmacology of Electronic Cigarettes
15636Teen Exposure to Active and Secondhand Tobacco Smoke
156511A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
156512A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel with or without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
15657A Phase 1/1b Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies
15658An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
157515A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies and Require Systemic Treatment
157521A Randomized Phase II Study of Pembrolizumab, an anti-PD(programmed cell death)-1 Antibody, in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease
15753An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis
15754Breast Capsular Contracture following Post-Mastectomy Reconstruction in Women Treated with the Leukotriene Inhibitor Zafirlukast: A Phase II Trial
15856A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers
159512A Phase 1 Open-Label First-in-human Dose-Escalating Safety and Tolerability Study Evaluating Subcutaneous Administration of Andes-1537 for Injection in Patients with Advanced Unresectable Solid Tumors that are Refractory to Standard Therapy or for Which No Standard Therapy is Available
159516A Phase Ib, Open-Label Study of Alpelisib (BYL719) in Combination with Cisplatin in Patients with HPV+ Solid Tumor Malignancies
159518A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects with Solid Tumors or CTCL and in Combination with Durvalumab and Palliative Radiation in Subjects with Solid Tumors
159520A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors
159522A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Select Biomarker Positive Advanced Solid Tumors (KEYNOTE-158)
15956A Phase 1, Open-Label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed against CD47, in Subjects with Advanced Solid and Hematologic Cancers
15959An Open-Label, Dose-Escalation and Multi-Center Study to Evaluate the Safety and Pharmacokinetics of SAR650984 in Patients with Relapsed/Refractory Multiple Myeloma
15981Molecular Profiling in Bone and Soft Tissue Malignancies
15989Preoperative Guided Imagery in Patients Undergoing Urology Surgery
15991Developing a Yoga Intervention During Cancer Chemotherapy
16-20051International Randomized Trial to Evaluate the Effectiveness of the Portable Organ Care System (OCS™) Liver for Preserving and Assessing Donor Livers for Transplantation (OCS Liver PROTECT Trial)
16-21273Sperm Selection by Microfluidic Separation Improves Embryo Quality in Patients with a History of Poor Embryo Quality
16081A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX-101) in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions
160816PNOC009: A Phase I and Early Efficacy Study of Convection Enhanced Delivery of Irinotecan Liposome Injection Using Real Time Imaging with Gadolinium in Children with Diffuse Intrinsic Pontine Glioma
160821Phase 1 Study of Pazopanib in Combination with Irinotecan and Temozolomide (PAZIT) for Children and Young Adults with Relapsed or Refractory Sarcoma
160823Multi-center, open-label randomized study of single or double myeloablative cord blood transplantation with or without infusion of off–the-shelf ex vivo expanded cryopreserved cord blood progenitor cells in patients with hematologic malignancies
160829Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
160830Matched Targeted Therapy (MTT) Recommendation for Patients with Recurrent, Refractory, or High Risk Leukemias
161010Emergency Use of Enzastaurin to Treat Recurrent Glioblastoma
161014A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects with Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma
161019Ivy Foundation Early Phase Clinical Trials Consortium: A Phase 2 Study of Abemaciclib in Recurrent Glioblastoma
161021Vigilant ObservatIon of GlIadeL WAfer ImplaNT (VIGILANT) Registry: A Multicenter, Observational Registry to Collect Information on the Safety and Effectiveness of Gliadel Wafer (Carmustine Implant) Used in Usual Medical Practice
16104A Randomized Phase 3 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma
16106Feasibility and Efficacy of an iPad-Based Cognitive Rehabilitation Program in Brain Tumor Patients
16109A Phase 2, Multicenter Study of Tesevatinib Monotherapy in Patients with Recurrent Glioblastoma
162010Nivolumab in Combination with Chemoradiation for Patients with Stage II-IVB Nasopharyngeal Carcinoma, A Phase II Study with Correlative Biomarkers
16202Employing Humanized NSG (hu-NSG) Mice for Testing Immune Modulators in Human Head and Neck Squamous Cell Carcinoma Xenografts
16203A Two-Arm, Open-label, Randomized Phase II Study of Pembrolizumab (MK-3475) Monotherapy versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)
16205A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
16251A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Protein Expression in Diffuse Large B-Cell Lymphoma
16252Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 directed CART Cell Therapy CCTL019A2205B
16253End-of-Life Care for Hematopoietic Stem Cell Transplant Recipients
16257Immune Monitoring During ASP2215 Therapy in Relapsed/Refractory Acute Myeloid Leukemia (AML) CPRC# 2016NTLS038
16259Retrospective Study Correlating Multiple Myeloma Minimal Residual Disease by Clonoseq with Patient Outcomes
16451A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma
164511Survivor Choices for Eating and Drinking (SUCCEED) – Colorectal Cancer
164512Multi-Center Chart Review Study in the US to Examine Treatment Patterns and Associated Outcomes among Patients with Advanced Neuroendocrine Tumors (NET) of Gastrointestinal (GI) Origin
164513Multi-Center Chart Review Study in the US to Examine Treatment Patterns and Associated Outcomes among Patients with Advanced Neuroendocrine Tumors (NET) of Lung Origin
164516Pancreatic Cancer Radiotherapy Study Group (PanCRS) Trial: A Randomized Phase III Study Evaluating Modified FOLFIRINOX (mFFX) with or without Stereotactic Body Radiotherapy (SBRT) in the Treatment of Locally Advanced Pancreatic Cancer
164518A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
164519Circulating Tumor Derived Cell-free DNA as a Novel Biomarker to Predict Recurrence of Colorectal Cancer
16452Phase I/II Study of TAS-102 and Radioembolization with 90Y Resin Microspheres for Chemo-Refractory Colorectal Hepatic Metastases
164520Sharing Clinical and Genomic Data for Cancer Research
16455Expanded Access Protocol for Therapeutic Use of 177Lu-DOTA0-Tyr3-Octreotate in Patients with Inoperable, Somatostatin Receptor Positive, Midgut Carcinoid Tumors, Progressive Under Somatostatin Analogue Therapy
16458A Multicenter Phase I/II Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients
16459A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer
16527A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations
16551A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men with Biopsy Proven Low-Grade Prostate Cancer who are Candidates for Active Surveillance (proSPECT-AS)
165511Targeting Adaptive Pathways in Abiraterone and Enzalutamide Refractory Intermediate Atypical Carcinoma
165513A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
165514A PrOspective Phase 2/3 Multi-Center, Open-Label Study of 18F-DCFPyL PET/CT Imaging in Patients with PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY)
16552A Phase 1b, Open-Label Study of the Safety and Tolerability of Atezolizumab in Combination with Radium-223 Dichloride in Patients with Castrate-Resistant Prostate Cancer who have Progressed Following Treatment with an Androgen Pathway Inhibitor
16553Metastatic Standard Treatment Long Term Outcomes Evaluation
16556Prognostic Factors for Predicting Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Sipuleucel-T(Provenge)
16557Phase 2 open label study of pembrolizumab in patients with metastatic castration resistant prostate cancer (mCRPC) with or without DNA damage repair defects
16559Gallium-68 PSMA-11 PET in intermediate to high-risk preprostatectomy patients
166511Phase II Trial of TG4010 plus Nivolumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
166512A Phase I/II study of Ceritinib + Trametinib in Patients with Advanced ALK-Positive NSCLC
166518A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer
166519Prospective genomic analysis of cell-free tumor DNA in advanced EGFR-mutant lung cancer patients treated with an EGFR TKI
166520PembroX: Enhancing the Immunogenicity of Non-Small Cell Lung Cancer with Pembrolizumab +/- Stereotactic Radiotherapy Delivered in the Preoperative Window, A Randomized Phase II Study with Correlative Biomarkers
166521Phase II trial to evaluate trametinib in patients with advanced NF1-mutant non-small cell lung cancer
167010Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
167012An Open-label, Phase IB study of NEO-PV-01 + Adjuvant with Nivolumab in Patients with Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder
16702A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers
16704Testing the Ability of Pembrolizumab to Alter the Tumor Immune MicroEnvironment (TIME) of High Risk DCIS
16706A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients with Unresectable or Metastatic B7-H3-Expressing Neoplasms and Neoplasms whose Vasculature Expresses B7-H3
16707A Phase 1, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CA-170 in Patients with Advanced Tumors and Lymphomas
16708A Phase I Open Label, Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRS Specific for Alpha-Fetoprotein (AFPC332T)in HLA-A2 Positive Subjects with Advanced Hepatocellular Carcinoma (HCC)
16709Functional Imaging of T-cell Activation with [18F]F-AraG in Bladder Cancer Patients Receiving Neoadjuvant or Standard of Care Atezolizumab
16751Fertility Preservation using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
167510Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
16752The WISDOM Study (Women Informed to Screen Depending on Measures of Risk)
16757A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer
16758A Phase 1b trial of the cyclin-dependent kinase inhibitor dinaciclib in combination with pembrolizumab in patients with advanced breast cancer and assessment of MYC oncogene overexpression
16759Second Opinions and the Treatment Gradient Experienced by African American Breast Cancer Patients: An Exploratory Study
16801Developing an Integrative Ayurvedic Intervention for Breast Cancer Survivorship
16802Treatment of breast cancer-related LE with a negative pressure device: a pilot randomized controlled study
16855A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors
16856Health eHeart-CardioOncology and Immunotherapy Pilot study (HeH-COIP)
16871Retrospective Analysis of Neo-adjuvant Chemotherapy in Pleomorphic Soft Tissue Sarcoma Patients Treated at UCSF
169513An Open-Label, Phase 1b, Multi-Arm Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination with Standard of Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma
169517A Phase I Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, or Pancreatic Cancer
169519A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors
16952A Phase 1 Safety and Tolerability Study of ZEN003694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
169521Combination therapy of Rucaparib and Irinotecan in cancers with DNA repair mutations
169522A First-in-Human Phase 1/2a Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of FF-10101-01 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia
169524A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
16953A Phase Ib/II Multi-Arm Study with Venetoclax in Combination with Cobimetinib and Venetoclax in Combination with Idasanutlin in Patients Aged >= 60 Years with Relapsed or Refractory Acute Myeloid Leukemia who are not Eligible for Cytotoxic Therapy
16954Phase 1/2 Study of CORT125134 in Combination with Nab-paclitaxel in Patients with Solid Tumors
16957Phase 1/2 Clinical Study of Niraparib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Triple-Negative Breast Cancer and in Patients with Recurrent Ovarian Cancer
169810Retrospective Analysis of Radiotherapy Techniques and Outcomes
16983Biospecimen Acquisition Protocol for Analysis of Biomarkers in Cancers
17-21815Immunogenicity of Nonavalent HPV Vaccine Administered Prior To Living Donor Renal Transplantation in Adult Women: A Prospective, Single-Arm, Multi-Center Clinical Trial
171016A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies
17108A Phase II, Open-Label, Single Arm, Multicenter Study of Avelumab with Hypofractionated re-irradiation in Adult Subjects with Transformed IDH Mutant Glioblastoma
17109Ivy Foundation Early Phase Clinical Trials Consortium BioTarget Protocol
17204A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
17209A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma (KEYNOTE-412)
172516RAIN (Renal AL amyloid Involvement and NEOD001): A Multicenter Randomized Double-blind Phase 2b Study of NEOD001 in Previously Treated Subjects with Systemic Light-chain (AL) Amyloidosis and Persistent Renal Involvement
17254A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination with Corticosteroids versus Placebo in Combination with Corticosteroids in Subjects with New Onset Chronic Graft versus Host Disease (cGVHD)
17256Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation
17401ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
17403A Phase III, Multi-center, Randomized Study of Atezolizumab versus Placebo Administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab to Patients with Newly Diagnosed Stage III or State IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
17404A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
17451A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation
174523Multicenter Pilot Study of the Safety, Efficacy, and Immune Cell Profiling in Advanced Hepatocellular Carcinoma (HCC) Patients Treated with the Combination of Sorafenib plus Nivolumab as First-Line of Systemic Therapy
17455Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor
17457A Dose-Finding Phase 1 Study Of Tas-120 In Patients With Advanced Solid Tumors With Or Without Fibroblast Growth Factor/Receptor (Fgf/Fgfr)-Related Abnormalities Followed By A Phase 2 Study In Patients With Advanced Solid Tumors With Fgf/Fgfr-Related Abnormalities
17459Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver (RETNET): A phase 2 randomized multicenter trial to compare hepatic progression-free survival following bland embolization, lipiodol chemoembolization, and drug-eluting bead chemoembolization of neuroendocrine liver metastases
175518Gallium-68 PSMA-11 PET in patients with biochemical recurrence
17556A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician’s Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency
17651Randomized, Double-Blind, Phase 2/3 Study in Subjects with Malignant Pleural Mesothelioma with Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 with Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)
17701A Pilot Study of APX005M in Combination with Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers
17704A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma
17707A Randomized, Phase 2 Study of Ipilimumab vs Ipilimumab plus Nivolumab in Patients with Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
17751A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs. Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer- (KEYNOTE-355)
177514A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer
17752A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With Anthracycline, A Taxane, and Capecitabine
177525A Phase II, Multicenter, open-label, two-cohort, non-comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK4/6 inhibitor treatment
17756A PHASE 1B OPEN-LABEL THREE-ARM MULTI-CENTER STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF PF-05212384 (PI3K/MTOR INHIBITOR) IN COMBINATION WITH OTHER ANTI-TUMOR AGENTS
17854Prostaglandin Inhibition and PD-1/CTLA4 blockade in Melanoma
17951A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF ORAL ENTRECTINIB (RXDX-101) IN ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCER CONFIRMED TO BE POSITIVE FOR NTRK1, NTRK2, NTRK3, ROS1, OR ALK MOLECULAR ALTERATIONS
7163-CL-3201A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de novo Kidney Transplant Recipients
AALL0932Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)
AALL1331Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
AALL1521A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia
AAML1331A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All- Trans Retinoic Acid
AAML1421Phase 1/2 Study of CPX-351 (NSC# 775341; IND #129443) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML)
ABTC-1301Pilot Study of MLN0128 (TAK-228) in Preoperative Recurrent Glioblastoma (GBM) Patients
ABTC-1602Single-arm, Open-label Phase II Efficacy Study of First-in-class HIF2-Alpha Inhibitor, PT2385, for Patients with Recurrent Glioblastoma
ACEAllergen Challenge for Evoked Phenotypes in Asthma
ACNS0831Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years
ADVL1312A Phase 1/2 Study of AZD1775 (MK-1775, IND# 121422) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
ADVL1322A Phase II Trial of Pazopanib NSC# 737754, IND# 65747 in Children with Refractory Solid Tumors
ADVL1411A Phase 1/2 Study of BMN 673 (IND# 121510), an Oral POLY(ADP-RIBOSE) Polymerase Inhibitor, plus Temozolomide in Children with Refractory or Recurrent Malignancies
ADVL1412A Phase 1/2 Study of Nivolumab (IND#124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
ADVL1416A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors
ADVL1513A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
ADVL1515A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
AEWS1221-CIRBRandomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
ALLIANCE-A011401Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
ALLIANCE-A051301A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
ALLIANCE-A071102A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation
ALLIANCE-A071401Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations
ALLTOL-ITN063STALLTOL: A Prospective Cohort Study of Operationally Tolerant Allograft Recipients
AMC-088A Randomized, Phase III Study of Intra-anal imiquimod 2.5% vs. Topical 5-fluorouracil 5% vs. Observation for the Treatment of High-grade Anal Squamous Intraepithelial Lesions in HIV-infected Men and Women
AMC-092A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons
AMC-095A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors
ANHL12P1A Randomized Phase II study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma (ALCL) IND #117117
ANHL1522A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)
AOST1321Phase 2 Study of Denosumab (IND# 127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma
ARST1321Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)
ATM-96814A Single-Center, Non-Randomized Study of the Safety and Efficacy of In Utero Hematopoietic Stem Cell Transplantation for the Treatment of Fetuses with Alpha Thalassemia Major
BMT-CTN-1506A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML
CLN-PRO-V004A Phase 2 Study for the Evaluation of Safety and Efficacy of Humacyte’s Human Acellular Vessel for Use as a Vascular Prosthesis for Femoro-Popliteal Bypass in Patients with Peripheral Arterial Disease
CTOT-19Randomized Controlled Trial of Infliximab Induction Therapy for Deceased Donor Kidney Transplant Recipients
CTOTC-12Safety of Donor Alloantigen Reactive Tregs (darTregs) to Facilitate Minimization and/or Discontinuation of Immunosuppression in Adult Liver Transplant Recipients (ARTEMIS)
CTSU-NCCTG-N1048A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
CTSU-NRG-HN001Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
CTSU-S1207Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
CTSU-S1320A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma
CVHRStudy Comparing the Efficacy, Safety, and Cost of a Permanent, Synthetic Prosthetic Versus a Biologic Prosthetic in the One-stage Repair of Ventral Hernias in Clean and Contaminated Wounds.
DBS-TINNITUSU01Pilot Study of Deep Brain Stimulation in Area LC for Chronic Tinnitus
DIABETES-PORE-CONTENTRevealing the nature and longitudinal evolution of type 2 diabetic bone disease
GOG-3009A Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV
GOG-3012A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
HIVTR-CCR5Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients
HIVTR-EVEImpact of Everolimus on HIV Persistence Post Kidney (and Kidney/Pancreas) or Liver Transplant
HIVTR-HOPEA Prospective Observational Study of Solid Organ Transplantation Utilizing HIV-Positive Donors in HIV-Positive Recipients
HOLIDAYThe HOLIDAY (HOw ALcohol InDuces Atrial TachYarrhythmias) Study
INVOCELLComparing intra-vaginal culture of embryos using INVOcell device to in-vitro culture of embryos
ITN056STEvaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Operational Tolerance Following Liver Transplantation in Adults
KOHI-ASafety and Efficacy of Embozene® Microspheres for Uterine Fibroid Embolization Compared to Embosphere® Microspheres for Symptomatic Relief from Uterine Fibroids
NANT-2004-05NANT2004-05: Neuroblastoma Biology Study
NANT-2011-01Randomized Phase II Study of 131I-MIBG versus 131I-MIBG with Vincristine and Irinotecan versus 131I-MIBG with Vorinostat for Resistant/Relapsed Neuroblastoma
NANT-2011-04A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients with Refractory/Recurrent Neuroblastoma
NANT-2012-01Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib with Cyclophosphamide/Topotecan for Patients with Relapsed or Refractory Neuroblastoma
NANT-2013-02A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients with Relapsed and Refractory Neuroblastoma
NANT-2014-01Phase I Study of SF1126 for Patients with Relapsed or Refractory Neuroblastoma
NANT-2015-01Neuroblastoma Precision Trial
OMEGA-SPMTHE OMEGA-SPM-DOSE and OMEGA-SPM-PAD STUDIES: Specialized Pro-Resolving Mediators in Patients with Peripheral Artery Disease
ONE-FREEZE-1SF2014ONE FREEZE: A prospective multi-center randomized controlled trial to assess the safety and efficacy of one vs. two cryoablations per pulmonary vein for the treatment of atrial fibrillation
ONEDARTREG14Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Renal Transplantation: A ONE Study Clinical Trial
PAKTPAKT Biospecimen Registry
PBTC-029BA Phase I and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
PRT-201-320Multicenter, Double-Blind, Placebo-Controlled Study of Vonapanitase (PRT-201) Administered Immediately after Radiocephalic Arteriovenous Fistula Creation in Patients with Chronic Kidney Disease
REP0112A phase 2/3, multicenter, randomized, double-blind, placebo-controlled, parallel assignment study to assess the efficacy and safety of reparixin in pancreatic islet auto-transplantation.
SGTP002-SANGUINATEA Randomized, Placebo-controlled, Prospective, Double-blind, Multicenter Phase 2/3 Study of the Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Recipients of a Donation after Brain Death Kidney Transplant
TACL-2014-001A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
TILTA Phase 1 Trial of CD4+CD127lo/-CD25+ Polyclonal Treg Adoptive Immunotherapy with Interleukin-2 for the Treatment of Type 1 Diabetes
TINNITUS-DODTinnitus Multimodal Imaging
WPO1-ORGANOXA multicenter randomized controlled trial to compare the efficacy of ex-vivo normothermic machine perfusion with static cold storage in human liver transplantation